CHADDS FORD, Pa., Dec. 22 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals Inc., a wholly owned subsidiary of Endo Pharmaceuticals Holdings Inc. , today announced that it has filed what it believes are complete responses to the U.S. Food and Drug Administration’s (FDA) approvable letters on the company’s New Drug Applications (NDAs) for each of its investigational products oxymorphone extended-release (oxymorphone ER) and immediate-release (oxymorphone IR) tablets. As previously disclosed on October 20, 2003, the FDA issued approvable letters for oxymorphone ER and IR tablets but had requested that Endo address certain questions and provide more clarification and information, including data from additional clinical trials to further confirm the safety and efficacy of these products.
Under the Prescription Drug User Fee Act (PDUFA) guidelines, the FDA has 60 days to decide if today’s submissions meet its criteria for a complete response and, if so, the company expects that the FDA will issue an action letter for each NDA no later than 180 days from today.
“We look forward to working with the FDA to bring both of these products to market,” said Peter A. Lankau, president and chief executive officer. “We believe that oxymorphone is the most extensively studied oral opioid, including a data set of more than 3,000 patients. We also believe oxymorphone ER will give physicians an important new option for treating patients with moderate-to-severe chronic pain who require around-the-clock opioid therapy for longer than a few days.” He noted that oxymorphone ER is the only opioid analgesic to have been studied in two placebo-controlled, 12-week trials in both opioid-naive and opioid-experienced patients and to have demonstrated statistically (p<0.0001) and clinically significant efficacy in these patient populations. “In addition, oxymorphone IR has been well studied for the treatment of acute moderate-to-severe pain, and we see it as a valuable complement to the extended-release formulation, as is our current intravenous formulation for hospital use,” Lankau added.
“If approved, Endo will be prepared to launch oxymorphone ER and IR in the second half of 2006,” Lankau said. Oxymorphone ER would compete in the market for long-acting, strong opioids, a $4.2 billion market in 2004.
To meet the FDA’s request for more clinical information for oxymorphone ER, Endo conducted two separate multi-center, randomized, double-blind, parallel group trials evaluating this product in two distinct groups of patients with chronic low back pain: opioid-naive and opioid-experienced. The trial involving opioid-naive patients was conducted under the FDA’s Special Protocol Assessment (SPA) process.
The company also reported that today’s filing included previously disclosed positive results for a placebo-controlled, multi-center Phase III trial for oxymorphone IR in the treatment of acute post-operative pain. Endo also conducted this study under the FDA’s SPA process. The data from the two new oxymorphone ER Phase III studies and from the one oxymorphone IR Phase III study will supplement the previously submitted Phase III trials for both products that the company believes the FDA already has accepted as demonstrating efficacy in the intended patient populations.
About Oxymorphone
Oxymorphone ER is a semi-synthetic mu-opioid agonist that has been formulated as a 12-hour extended-release tablet using Penwest Pharmaceuticals’ proprietary time-release technology, TIMERx(R) delivery system. Oxymorphone ER has been studied in a wide range of chronic pain conditions, including low back pain, osteoarthritis pain, post-surgical pain and cancer pain. Oxymorphone ER is currently under review by the FDA. The safety and efficacy of oxymorphone ER have not been established by the FDA.
Oxymorphone IR has been studied in post-surgical pain in doses varying from 5 to 20 mg. Oxymorphone IR is currently under review by the FDA. The safety and efficacy of oxymorphone IR have not been established by the FDA.
Oxymorphone is a Schedule II controlled substance.
Respiratory depression is the chief hazard from all opioid agonists including oxymorphone preparations. Respiratory depression is a particular potential problem in elderly or debilitated patients as well as in those suffering from conditions accompanied by hypoxia or hypercapnia when even moderate therapeutic doses may dangerously decrease pulmonary ventilation. The most common adverse reactions reported by patients treated with oxymorphone ER during clinical trials were nausea, constipation, dizziness, pruritus (itching), vomiting, somnolence, increased sweating, sedation and headache.
About Endo
A wholly owned subsidiary of Endo Pharmaceuticals Holdings , Endo Pharmaceuticals Inc. is a fully integrated specialty pharmaceutical company with market leadership in pain management products. The company researches, develops, produces and markets a broad product offering of both branded and generic pharmaceuticals, meeting the needs of healthcare professionals and consumers alike. More information, including this and past press releases of Endo Pharmaceuticals Holdings Inc., is available online at www.endo.com.
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on management’s beliefs and assumptions, current expectations, estimates and projections. Statements that are not historical facts, including statements which are preceded by, followed by, or that include, the words “believes,” “anticipates,” “plans,” “expects” or similar expressions and statements are forward-looking statements. Endo’s estimated or anticipated future results, product performance or other non- historical facts are forward-looking and reflect Endo’s current perspective on existing trends and information. Many of the factors that will determine the Company’s future results are beyond the ability of the Company to control or predict. These statements are subject to risks and uncertainties and, therefore, actual results may differ materially from those expressed or implied by these forward-looking statements. The reader should not rely on any forward-looking statement. The Company undertakes no obligation to update any forward-looking statements whether as a result of new information, future events or otherwise. Several important factors, in addition to the specific factors discussed in connection with these forward-looking statements individually, could affect the future results of Endo and could cause those results to differ materially from those expressed in the forward-looking statements contained in this press release. Important factors that may affect future results include, but are not limited to: market acceptance of the Company’s products and the impact of competitive products and pricing; dependence on sole source suppliers; the success of the Company’s product development activities and the timeliness with which regulatory authorizations and product launches may be achieved; successful compliance with extensive, costly, complex and evolving governmental regulations and restrictions; the availability on commercially reasonable terms of raw materials and other third party manufactured products; exposure to product liability and other lawsuits and contingencies; dependence on third party suppliers, distributors and collaboration partners; the ability to timely and cost effectively integrate acquisitions; uncertainty associated with pre-clinical studies and clinical trials and regulatory approval; uncertainty of market acceptance of new products; the difficulty of predicting FDA approvals; risks with respect to technology and product development; the effect of competing products and prices; uncertainties regarding intellectual property protection; uncertainties as to the outcome of litigation; changes in operating results; impact of competitive products and pricing; product development; changes in laws and regulations; customer demand; possible future litigation; availability of future financing and reimbursement policies of government and private health insurers and others; and other risks and uncertainties detailed in Endo’s filings with the Securities and Exchange Commission, including its Registration Statement on Form S-3 filed with the SEC on April 30, 2004, as amended and in Endo’s Registration Statement on Form S-3 filed with the SEC on September 2, 2005, as amended. Readers should evaluate any statement in light of these important factors.
CONTACT:
Bill Newbould
(610) 558-9800
Endo Pharmaceuticals Inc.
CONTACT: Bill Newbould for Endo Pharmaceuticals Inc., +1-610-558-9800
Web site: http://www.endo.com/
